The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
DOPAL initiates αSynuclein-dependent impaired proteostasis and degeneration of neuronal projections in Parkinson’s disease
Abstract
Dopamine dyshomeostasis has been acknowledged among the determinants of nigrostriatal neuron degeneration in Parkinson’s disease (PD). Several studies in experimental models and postmortem PD patients underlined increasing levels of the dopamine metabolite 3,4-dihydroxyphenylacetaldehyde (DOPAL), which is highly reactive towards proteins. DOPAL has been shown to covalently modify the presynaptic protein αSynuclein (αSyn), whose misfolding and aggregation represent a major trait of PD pathology, triggering αSyn oligomerization in dopaminergic neurons. Here, we demonstrated that DOPAL elicits αSyn accumulation and hampers αSyn clearance in primary neurons. DOPAL-induced αSyn buildup lessens neuronal resilience, compromises synaptic integrity, and overwhelms protein quality control pathways in neurites. The progressive decline of neuronal homeostasis further leads to dopaminergic neuron loss and motor impairment, as showed in in vivo models. Finally, we developed a specific antibody which detected increased DOPAL-modified αSyn in human striatal tissues from idiopathic PD patients, corroborating the translational relevance of αSyn-DOPAL interplay in PD neurodegeneration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kaushik, S., & Cuervo, A. M. (2015) · Nature Medicine · doi:10.1038/nm.4001 · Cited by 899
Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson’s disease
Burbulla, L. F., Song, P., Mazzulli, J. R., Zampese, E., Wong, Y. C., Jeon, S., Santos, D. P., Blanz, J., Obermaier, C. D., Strojny, C., et al. (2017) · Science · doi:10.1126/science.aam9080 · Cited by 874
Defining midbrain dopaminergic neuron diversity by single-cell gene expression profiling
Poulin, J.-F., Zou, J., Drouin-Ouellet, J., Kim, K.-Y. A., Cicchetti, F., & Awatramani, R. B. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.10.008 · Cited by 352
Kinetic and Structural Analysis of the Early Oxidation Products of Dopamine
Bisaglia, M., Mammi, S., & Bubacco, L. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m610893200 · Cited by 303
Self-citationNorris, E. H., Giasson, B. I., Hodara, R., Xu, S., Trojanowski, J. Q., Ischiropoulos, H., & Lee, V. M.-Y. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m412621200 · Cited by 273
Retrograde Axonal Degeneration in Parkinson Disease
Tagliaferro, P., & Burke, R. E. (2016) · Journal of Parkinson’s Disease · doi:10.3233/jpd-150769 · Cited by 272
Aldehyde dehydrogenase 1 defines and protects a nigrostriatal dopaminergic neuron subpopulation
Liu, G., Yu, J., Ding, J., Xie, C., Sun, L., Rudenko, I., Zheng, W., Sastry, N., Luo, J., Rudow, G., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72176 · Cited by 166
Farfel-Becker, T., Roney, J. C., Cheng, X.-T., Li, S., Cuddy, S. R., & Sheng, Z.-H. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.06.013 · Cited by 152
Research works printed but not linked: 81
- Brichta, L. & Greengard, P. Molecular determinants of selective dopaminergic vulnerability in Parkinson’s disease: an update. Front. Neuroanat. 8, 152 (2014). · DOI · Paper page
- Surmeier, D. J., Obeso, J. A. & Halliday, G. M. Selective neuronal vulnerability in Parkinson disease. Nat. Rev. Neurosci. 18, 101–113 (2017). · DOI · Paper page
- Bolam, J. P. & Pissadaki, E. K. Living on the edge with too many mouths to feed: Why dopamine neurons die. Mov. Disord. 27, 1478–1483 (2012). · DOI · Paper page
- Graves, S. M. et al. Dopamine metabolism by a monoamine oxidase mitochondrial shuttle activates the electron transport chain. Nat. Neurosci. 23, 15–20 (2020). · DOI · Paper page
- Wang, Y.-C., Lauwers, E. & Verstreken, P. Presynaptic protein homeostasis and neuronal function. Curr. Opin. Genet. Dev. 44, 38–46 (2017). · DOI
- Janezic, S. et al. Deficits in dopaminergic transmission precede neuron loss and dysfunction in a new Parkinson model. Proc. Natl Acad. Sci. USA 110, E4016–E4025 (2013). · DOI · Paper page
- Mor, D. E. et al. Dopamine induces soluble α-synuclein oligomers and nigrostriatal degeneration. Nat. Neurosci. 20, 1560–1568 (2017). · DOI · Paper page
- Wegrzynowicz, M. et al. Depopulation of dense α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson’s disease model. Acta Neuropathol. 138, 1–21 (2019). · DOI
- Goldstein, D. S. et al. Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinson’s disease. J. Neurochem. 126, 591–603 (2013). · DOI · Paper page
- Burke, W. J., Li, S. W., Williams, E. A., Nonneman, R. & Zahm, D. S. 3,4-Dihydroxyphenylacetaldehyde is the toxic dopamine metabolite in vivo: implications for Parkinson’s disease pathogenesis. Brain Res. 989, 205–213 (2003). · DOI · Paper page
- Masato, A., Plotegher, N., Boassa, D. & Bubacco, L. Impaired dopamine metabolism in Parkinson’s disease pathogenesis. Mol. Neurodegener. 14, 35 (2019). · DOI · Paper page
- Cruz, F. & Edmondson, D. E. Kinetic properties of recombinant MAO-A on incorporation into phospholipid nanodisks. J. Neural Transm. 114, 699–702 (2007). · doi:10.1007/s00702-007-0673-0
- Umek, N., Geršak, B., Vintar, N., Šoštarič, M. & Mavri, J. Dopamine autoxidation is controlled by acidic pH. Front. Mol. Neurosci. 11, 467 (2018). · DOI
- Salomäki, M., Marttila, L., Kivelä, H., Ouvinen, T. & Lukkari, J. Effects of pH and oxidants on the first steps of polydopamine formation: a thermodynamic approach. J. Phys. Chem. B 122, 6314–6327 (2018). · DOI · Paper page
- Rees, J. N., Florang, V. R., Eckert, L. L. & Doorn, J. A. Protein reactivity of 3,4-dihydroxyphenylacetaldehyde, a toxic dopamine metabolite, is dependent on both the aldehyde and the catechol. Chem. Res. Toxicol. 22, 1256–1263 (2009). · DOI
- Pifl, C. et al. Is Parkinson’s disease a vesicular dopamine storage disorder? Evidence from a study in isolated synaptic vesicles of human and nonhuman primate striatum. J. Neurosci. 34, 8210–8218 (2014). · DOI · Paper page
- Nicotra, A., Pierucci, F., Parvez, H. & Senatori, O. Monoamine oxidase expression during development and aging. NeuroToxicology 25, 155–165 (2004). · DOI · Paper page
- Grunblatt, E. et al. Gene expression profiling of parkinsonian substantia nigra pars compacta; alterations in ubiquitin-proteasome, heat shock protein, iron and oxidative stress regulated proteins, cell adhesion/cellular matrix and vesicle trafficking genes. J. Neural Transm. 111, 1543–1573 (2004). · DOI · Paper page
- Mandel, S. A., Fishman, T. & Youdim, M. B. H. Gene and protein signatures in sporadic Parkinson’s disease and a novel genetic model of PD. Parkinsonism Relat. Disord. 13, S242–S247 (2007). · DOI
- Plotegher, N. et al. DOPAL derived alpha-synuclein oligomers impair synaptic vesicles physiological function. Sci. Rep. 7, 40699 (2017). · DOI · Paper page
- Burke, W. J. et al. Aggregation of alpha-synuclein by DOPAL, the monoamine oxidase metabolite of dopamine. Acta Neuropathol. 115, 193–203 (2008). · DOI · Paper page
- Follmer, C. et al. Oligomerization and membrane-binding properties of covalent adducts formed by the interaction of a-synuclein with the toxic dopamine metabolite 3,4-dihydroxyphenylacetaldehyde (DOPAL). J. Biol. Chem. 290, 27660–27679 (2015). · DOI · Paper page
- Mazzulli, J. R., Armakola, M., Dumoulin, M., Parastatidis, I. & Ischiropoulos, H. Cellular oligomerization of α-Synuclein is determined by the interaction of oxidized catechols with a C-terminal sequence. J. Biol. Chem. 282, 31621–31630 (2007). · DOI
- Mazzulli, J. R., Burbulla, L. F., Krainc, D. & Ischiropoulos, H. Detection of free and protein-bound ortho-quinones by near-infrared fluorescence. Anal. Chem. 88, 2399–2405 (2016). · DOI
- Fellman, J. H. The rearrangement of epinephrine. Nature 182, 311–312 (1958). · doi:10.1038/182311a0
- Kumar, S. T. et al. How specific are the conformation-specific α-synuclein antibodies? Characterization and validation of 16 α-synuclein conformation-specific antibodies using well-characterized preparations of α-synuclein monomers, fibrils and oligomers with distinct structures and morphology. Neurobiol. Dis. 146, 105086 (2020). · DOI
- Butko, M. T. et al. Fluorescent and photo-oxidizing TimeSTAMP tags track protein fates in light and electron microscopy. Nat. Neurosci. 15, 1742–1751 (2012). · DOI
- Ellisman, M. H. et al. Advances in molecular probe-based labeling tools and their application to multiscale multimodal correlated microscopies. J. Chem. Biol. 8, 143–151 (2015). · DOI
- Utton, M. A., Noble, W. J., Hill, J. E., Anderton, B. H. & Hanger, D. P. Molecular motors implicated in the axonal transport of tau and α-synuclein. J. Cell Sci. 118, 4645–4654 (2005). · DOI · Paper page
- Shu, X. et al. A genetically encoded tag for correlated light and electron microscopy of intact cells, tissues, and organisms. PLoS Biol. 9, e1001041 (2011). · DOI · Paper page
- Boassa, D. et al. Mapping the subcellular distribution of -synuclein in neurons using genetically encoded probes for correlated light and electron microscopy: implications for Parkinson’s disease pathogenesis. J. Neurosci. 33, 2605–2615 (2013). · DOI
- Burré, J. The synaptic function of α-synuclein. J. Parkinsons Dis. 5, 699–713 (2015). · DOI · Paper page
- Logan, T., Bendor, J., Toupin, C., Thorn, K. & Edwards, R. H. α-Synuclein promotes dilation of the exocytotic fusion pore. Nat. Neurosci. 20, 681–689 (2017). · DOI · Paper page
- Fusco, G., Sanz-Hernandez, M. & De Simone, A. Order and disorder in the physiological membrane binding of α-synuclein. Curr. Opin. Struct. Biol. 48, 49–57 (2018). · DOI
- Wang, L. et al. The chaperone activity of heat shock protein 90 is critical for maintaining the stability of leucine-rich repeat kinase 2. J. Neurosci. 28, 3384–3391 (2008). · DOI · Paper page
- Boassa, D. et al. Split-miniSOG for spatially detecting intracellular protein-protein interactions by correlated light and electron microscopy. Cell Chem. Biol. 26, 1407–1416.e5 (2019). · DOI
- Alvarez-Erviti, L. et al. Lysosomal dysfunction increases exosome-mediated alpha-synuclein release and transmission. Neurobiol. Dis. 42, 360–367 (2011). · DOI · Paper page
- Danzer, K. M. et al. Exosomal cell-to-cell transmission of alpha synuclein oligomers. Mol. Neurodegener. 7, 42 (2012). · DOI · Paper page
- Binns, T. C. et al. Rational design of bioavailable photosensitizers for manipulation and imaging of biological systems. Cell Chem. Biol. 27, 1063–1072.e7 (2020). · DOI
- Tofaris, G. K. et al. Ubiquitin ligase Nedd4 promotes α-synuclein degradation by the endosomal-lysosomal pathway. Proc. Natl Acad. Sci. USA 108, 17004–17009 (2011). · DOI · Paper page
- Morgan, C. A., Parajuli, B., Buchman, C. D., Dria, K. & Hurley, T. D. N,N-diethylaminobenzaldehyde (DEAB) as a substrate and mechanism-based inhibitor for human ALDH isoenzymes. Chem. Biol. Interact. 234, 18–28 (2015). · DOI
- Wey, M. C.-Y. et al. Neurodegeneration and motor dysfunction in mice lacking cytosolic and mitochondrial aldehyde dehydrogenases: implications for Parkinson’s disease. PLoS ONE 7, e31522 (2012). · DOI · Paper page
- Lam, J. P., Mays, D. C. & Lipsky, J. J. Inhibition of recombinant human mitochondrial and cytosolic aldehyde dehydrogenases by two candidates for the active metabolites of disulfiram. Biochemistry 36, 13748–13754 (1997). · DOI
- Legros, H., Dingeval, M.-G., Janin, F., Costentin, J. & Bonnet, J.-J. Toxicity of a treatment associating dopamine and disulfiram for catecholaminergic neuroblastoma SH-SY5Y cells: relationships with 3,4-dihydroxyphenylacetaldehyde formation. Neurotoxicology 25, 365–375 (2004). · doi:10.1016/s0161-813x(03)00148-7
- Laplane, D., Attal, N., Sauron, B., De Billy, A. & Dubois, B. Lesions of basal ganglia due to disulfiram neurotoxicity. Neurosurg. Psychiatry 55, 925–929 (1992). · DOI
- Sun, Z. & Gitler, A. D. Discovery and characterization of three novel synuclein genes in zebrafish. Dev. Dyn. 237, 2490–2495 (2008). · DOI
- Toni, M. & Cioni, C. Fish synucleins: an update. Mar. Drugs 13, 6665–6686 (2015). · DOI
- Lulla, A. et al. Neurotoxicity of the Parkinson disease-associated pesticide ziram is synuclein-dependent in zebrafish embryos. Environ. Health Perspect. 124, 1766–1775 (2016). · DOI
- Fitzmaurice, A. G. et al. Aldehyde dehydrogenase inhibition as a pathogenic mechanism in Parkinson disease. Proc. Natl Acad. Sci. USA 110, 636–641 (2013). · DOI · Paper page
- Du, Y. et al. Spatial and temporal distribution of dopaminergic neurons during development in zebrafish. Front Neuroanat. 10, 115 (2016). · DOI
- Kroll, F. et al. A simple and effective f0 knockout method for rapid screening of behaviour and other complex phenotypes. Elife 10, 1–34 (2021). · DOI · Paper page
- Caudle, W. M. et al. Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration. J. Neurosci. 27, 8138–8148 (2007). · DOI · Paper page
- Conway, K. A., Rochet, J. C., Bieganski, R. M. & Lansbury, P. T. Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science 294, 1346–1349 (2001). · DOI · Paper page
- Mazzulli, J. R. et al. Cytosolic catechols inhibit -synuclein aggregation and facilitate the formation of intracellular soluble oligomeric intermediates. J. Neurosci. 26, 10068–10078 (2006). · DOI
- Bisaglia, M. et al. Dopamine quinones interact with α-synuclein to form unstructured adducts. Biochem. Biophys. Res. Commun. 394, 424–428 (2010). · DOI
- Rekas, A. et al. The structure of dopamine induced -synuclein oligomers. Eur. Biophys. J. 39, 1407–1419 (2010). · DOI
- Pantazopoulou, M. et al. Distinct alpha‐Synuclein species induced by seeding are selectively cleared by the Lysosome or the Proteasome in neuronally differentiated SH‐SY5Y cells. J. Neurochem. 156, 880–896 (2021). · DOI
- Li, W. et al. Stabilization of α-synuclein protein with aging and familial Parkinson’s disease-linked A53T mutation. J. Neurosci. 24, 7400–7409 (2004). · DOI · Paper page
- Martinez-Vicente, M. et al. Dopamine-modified α-synuclein blocks chaperone-mediated autophagy. J. Clin. Investig. 118, 777–778 (2008).
- Stykel, M. G. et al. α-Synuclein mutation impairs processing of endomembrane compartments and promotes exocytosis and seeding of α-synuclein pathology. Cell Rep. 35, 109099 (2021). · DOI
- Plotegher, N. & Bubacco, L. Lysines, Achilles’ heel in alpha-synuclein conversion to a deadly neuronal endotoxin. Ageing Res. Rev. 26, 62–71 (2016). · DOI
- Tozzi, A. et al. Dopamine-dependent early synaptic and motor dysfunctions induced by α-synuclein in the nigrostriatal circuit. Brain 144, 3477–3491 (2021). · DOI
- Hallengren, J., Chen, P.-C. & Wilson, S. M. Neuronal ubiquitin homeostasis. Cell Biochem. Biophys. 67, 67–73 (2013). · DOI
- Boecker, C. A. & Holzbaur, E. L. Vesicular degradation pathways in neurons: at the crossroads of autophagy and endo-lysosomal degradation. Curr. Opin. Neurobiol. 57, 94–101 (2019). · DOI
- Kageyama, S. et al. p62/SQSTM1-droplet serves as a platform for autophagosome formation and anti-oxidative stress response. Nat. Commun. 12, 16 (2021). · DOI · Paper page
- Kuusisto, E., Parkkinen, L. & Alafuzoff, I. Morphogenesis of Lewy bodies: dissimilar incorporation of α-synuclein, ubiquitin, and p62. J. Neuropathol. Exp. Neurol. 62, 1241–1253 (2003). · DOI · Paper page
- Shahmoradian, S. H. et al. Lewy pathology in Parkinson’s disease consists of crowded organelles and lipid membranes. Nat. Neurosci. 22, 1099–1109 (2019). · DOI · Paper page
- Mahul-Mellier, A. L. et al. The process of Lewy body formation, rather than simply α-synuclein fibrillization, is one of the major drivers of neurodegeneration. Proc. Natl Acad. Sci. USA 117, 4971–4982 (2020). · DOI · Paper page
- Koppaka, V. et al. Aldehyde dehydrogenase inhibitors: a comprehensive review of the pharmacology, mechanism of action, substrate specificity, and clinical application. Pharm. Rev. 64, 520–539 (2012). · DOI · Paper page
- Bellucci, A. et al. Redistribution of DAT/α-synuclein complexes visualized by “in situ” proximity ligation assay in transgenic mice modelling early Parkinson’s disease. PLoS ONE 6, e27959 (2011). · doi:10.1371/journal.pone.0027959
- Giordano, N. et al. Motor learning and metaplasticity in striatal neurons: relevance for Parkinson’s disease. Brain 141, 505–520 (2018). · DOI
- Salas-Leal, A. C. et al. rs3764435 associated with Parkinson’s disease in Mexican mestizos: case-control study reveals protective effects against disease development and cognitive impairment. Front. Neurol. 10, 1066 (2019). · DOI
- Fan, H.-H. et al. An antisense Alu transposon insertion/deletion polymorphism of ALDH1A1 may functionally associate with Parkinson’s disease. BMC Geriatr. 22, 1–10 (2022). · DOI
- Zhao, H. et al. Alpha-synuclein dopaminylation presented in plasma of both healthy subjects and Parkinson’s disease patients. Proteom. Clin. Appl. 14, e1900117 (2020). · DOI
- Masato, A., Sandre, M., Antonini, A. & Bubacco, L. Patients stratification strategies to optimize the effectiveness of scavenging biogenic aldehydes: towards a neuroprotective approach for Parkinson’s disease. Curr. Neuropharmacol. 19, 1618–1639 (2021). · DOI
- Meerbrey, K. L. et al. The pINDUCER lentiviral toolkit for inducible RNA interference in vitro and in vivo. Proc. Natl Acad. Sci. USA 108, 3665–3670 (2011). · DOI · Paper page
- López-Jiménez, A. et al. A spontaneous deletion of α-Synuclein is associated with an increase in CB1 mRNA transcript and receptor expression in the hippocampus and amygdala: effects on alcohol consumption. Synapse 67, 280–289 (2013). · doi:10.1002/syn.21639
- Zaltieri, M. et al. α-synuclein and synapsin III cooperatively regulate synaptic function in dopamine neurons. J. Cell Sci. 128, 2231–2243 (2015). · DOI · Paper page
- Berkhoudt Lassen, L. et al. ELISA method to detect α-synuclein oligomers in cell and animal models. PLoS ONE 13, e0196056 (2018). · DOI
- Kimmel, C. B., Ballard, W. W., Kimmel, S. R., Ullmann, B. & Schilling, T. F. Stages of embryonic development of the zebrafish. Dev. Dyn. 203, 253–310 (1995). · DOI · Paper page
- Mamais, A. et al. Divergent α-synuclein solubility and aggregation properties in G2019S LRRK2 Parkinson’s disease brains with Lewy Body pathology compared to idiopathic cases. Neurobiol. Dis. 58, 183–190 (2013). · DOI
Cited by
Role of dopamine in the pathophysiology of Parkinson’s disease
Zhou, Z. D., Yi, L. X., Wang, D. Q., Lim, T. M., & Tan, E. K. (2023) · Translational Neurodegeneration · doi:10.1186/s40035-023-00378-6 · Cited by 308
Metadata
- Authors
- Masato, A., Plotegher, N., Terrin, F., Sandre, M., Faustini, G., Thor, A., Adams, S., Berti, G., Cogo, S., De Lazzari, F., Fontana, C. M., Martinez, P. A., Strong, R., Bandopadhyay, R., Bisaglia, M., Bellucci, A., Greggio, E., Dalla Valle, L., Boassa, D., & Bubacco, L.
- Venue
- npj Parkinson's Disease
- Published
- 2023-03-25
- Volume
- 9
- Issue
- 1
- ISSN
- 2373-8057
- Cited by
- 39
- References
- 8
- Language
- en
- Licence
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: DOPAL initiates αSynuclein-dependent impaired proteostasis and degeneration of neuronal projections in Parkinson’s disease. https://app.cochat.ai/papers/10.1038/s41531-023-00485-1
- The paper
- Masato, A., Plotegher, N., Terrin, F., Sandre, M., Faustini, G., Thor, A., Adams, S., Berti, G., Cogo, S., De Lazzari, F., Fontana, C. M., Martinez, P. A., Strong, R., Bandopadhyay, R., Bisaglia, M., Bellucci, A., Greggio, E., Dalla Valle, L., Boassa, D., & Bubacco, L. (2023). DOPAL initiates αSynuclein-dependent impaired proteostasis and degeneration of neuronal projections in Parkinson’s disease. npj Parkinson's Disease. https://doi.org/10.1038/s41531-023-00485-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.